ATE546450T1 - Microkristall of (e)-8-(3,4-dimethoxystyryl)-1,3- diethyl-7-methyl-3,7-dihydro-1h-purine-2,6-dion - Google Patents

Microkristall of (e)-8-(3,4-dimethoxystyryl)-1,3- diethyl-7-methyl-3,7-dihydro-1h-purine-2,6-dion

Info

Publication number: ATE546450T1
Authority: AT; Austria
Prior art keywords: dimethoxystyryl; dione; purine; dihydro; diethyl
Prior art date: 2003-05-09

Application number

AT04731752T

Other languages

English (en)

Inventor

Kazutoshi Kuroda

Noboru Aoki

Toshiro Ochiai

Akihiro Uchida

Yasuhiro Ishikawa

Makoto Kigoshi

Eiji Hayakawa

Kazuki Asanome

Original Assignee

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-09

Filing date

2004-05-07

Publication date

2012-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33432132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE546450(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-07 Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE546450T1 publication Critical patent/ATE546450T1/de

Links

IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 title abstract 3
239000013081 microcrystal Substances 0.000 title abstract 3
239000002245 particle Substances 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
239000007787 solid Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AT04731752T 2003-05-09 2004-05-07 Microkristall of (e)-8-(3,4-dimethoxystyryl)-1,3- diethyl-7-methyl-3,7-dihydro-1h-purine-2,6-dion ATE546450T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2003131417		2003-05-09
PCT/JP2004/006495 WO2004099207A1 (ja)	2003-05-09	2004-05-07	微細結晶

Publications (1)

Publication Number	Publication Date
ATE546450T1 true ATE546450T1 (de)	2012-03-15

Family

ID=33432132

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04731752T ATE546450T1 (de)	2003-05-09	2004-05-07	Microkristall of (e)-8-(3,4-dimethoxystyryl)-1,3- diethyl-7-methyl-3,7-dihydro-1h-purine-2,6-dion

Country Status (10)

Country	Link
US (1)	US7541363B2 (de)
EP (1)	EP1626049B1 (de)
JP (2)	JP4606326B2 (de)
KR (2)	KR101229594B1 (de)
CN (1)	CN100395245C (de)
AT (1)	ATE546450T1 (de)
AU (1)	AU2004236101B2 (de)
CA (1)	CA2525037C (de)
ES (1)	ES2384685T3 (de)
WO (1)	WO2004099207A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2528385C (en) *	2003-06-06	2011-03-15	Endacea, Inc.	A1 adenosine receptor antogonists
TW200507882A (en) *	2003-07-17	2005-03-01	Kyowa Hakko Kogyo Kk	Solid formulations
JP7519782B2 (ja) *	2019-02-15	2024-07-22	日本ケミファ株式会社	パーキンソン病治療薬の安定化方法
JP7382737B2 (ja) *	2019-05-13	2023-11-17	東和薬品株式会社	イストラデフィリン製剤
CN113024558A (zh) *	2021-03-15	2021-06-25	山东新华制药股份有限公司	伊曲茶碱的晶体的制备方法和应用
TW202448478A (zh)	2023-02-24	2024-12-16	日商日本化美化股份有限公司	具有ｐ２ｘ４受體拮抗作用之化合物的固體分散體

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0059091A1 (de) *	1981-02-25	1982-09-01	Leslie Stott	Einrichtung zum Regeln der Ausflussmenge
US5484920A (en)	1992-04-08	1996-01-16	Kyowa Hakko Kogyo Co., Ltd.	Therapeutic agent for Parkinson's disease
PT628311E (pt) *	1992-07-08	2002-09-30	Kyowa Hakko Kogyo Kk	Derivado de xantina com actividade antidepressiva
JP2613355B2 (ja)	1992-09-28	1997-05-28	協和醗酵工業株式会社	パーキンソン氏病治療剤
US6254889B1 (en)	1995-07-26	2001-07-03	Kyowa Hakko Kogyo Co., Ltd.	Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
JPH0940652A (ja) *	1995-07-28	1997-02-10	Kyowa Hakko Kogyo Co Ltd	ウラシル誘導体の製造方法
TW200507882A (en) *	2003-07-17	2005-03-01	Kyowa Hakko Kogyo Kk	Solid formulations

2004
- 2004-05-07 AT AT04731752T patent/ATE546450T1/de active
- 2004-05-07 KR KR1020057020738A patent/KR101229594B1/ko not_active Expired - Fee Related
- 2004-05-07 AU AU2004236101A patent/AU2004236101B2/en not_active Ceased
- 2004-05-07 EP EP04731752A patent/EP1626049B1/de not_active Expired - Lifetime
- 2004-05-07 JP JP2005506044A patent/JP4606326B2/ja not_active Expired - Lifetime
- 2004-05-07 KR KR1020117026513A patent/KR20110128216A/ko not_active Ceased
- 2004-05-07 US US10/554,511 patent/US7541363B2/en not_active Expired - Lifetime
- 2004-05-07 CA CA2525037A patent/CA2525037C/en not_active Expired - Fee Related
- 2004-05-07 CN CNB2004800118737A patent/CN100395245C/zh not_active Expired - Fee Related
- 2004-05-07 ES ES04731752T patent/ES2384685T3/es not_active Expired - Lifetime
- 2004-05-07 WO PCT/JP2004/006495 patent/WO2004099207A1/ja not_active Ceased
2010
- 2010-06-17 JP JP2010138014A patent/JP2010195836A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1626049A4 (de)	2008-07-02
CN1784405A (zh)	2006-06-07
CN100395245C (zh)	2008-06-18
CA2525037A1 (en)	2004-11-18
JPWO2004099207A1 (ja)	2006-07-13
WO2004099207A1 (ja)	2004-11-18
AU2004236101A1 (en)	2004-11-18
EP1626049A1 (de)	2006-02-15
KR20110128216A (ko)	2011-11-28
ES2384685T3 (es)	2012-07-11
JP2010195836A (ja)	2010-09-09
US7541363B2 (en)	2009-06-02
CA2525037C (en)	2011-12-20
US20060205745A1 (en)	2006-09-14
AU2004236101B2 (en)	2010-11-11
JP4606326B2 (ja)	2011-01-05
EP1626049B1 (de)	2012-02-22
KR20060015570A (ko)	2006-02-17
KR101229594B1 (ko)	2013-02-05

Similar Documents

Publication	Publication Date	Title
NO2014008I1 (no)	2014-06-02	8-(3-aminopiperidin-1-yl)-7-but-2-inyl-3-metyl-1-(4-metylkinazolin-2-ylmetyl)-3,7-dihydropurin-2,6-dion, enantiomerene og saltene derav - spesielt Linagliptin ((R)-8-(3-aminopiperidin-1-yl)-7-but-2-inyl-3-metyl-1-(4-metylkinazolin-2-ylmetyl)-3,7-dihydropurin-2,6-dion-forbindelse (142) side 108 og blant annet kravene 1 og 5 i beskrivelsen
AU3397901A (en)	2001-09-12	2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents
DE502004007000D1 (de)	2008-06-12	Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2002046193A3 (en)	2003-02-27	Heterocyclic ether substituted imidazoquinolines
USD482370S1 (en)	2003-11-18	Pump for circulating coolant in electronic devices
DE502004006219D1 (de)	2008-03-27	Neue 8-(piperazin-1-yl)- und 8-( 1,4 diazepan-1-yl)-xanthine, deren herstellung und deren verwendung als arzneimittel
WO2003041647A3 (en)	2003-11-20	Synthesis and purification of valacyclovir
ZA200506253B (en)	2008-05-28	Pyrimidine derivatives for the prevention of HIV infection
PL377239A1 (pl)	2006-01-23	Nowe amino-podstawione pochodne dihydropirymido [4,5-d]-pirymidynonu, ich wytwarzanie i zastosowanie jako środków framaceutycznych
USD481137S1 (en)	2003-10-21	Artificial wood wall base
EP1864975A3 (de)	2008-01-23	Nicotinamide und deren Verwendung als P38 Inhibitoren
WO2005003065A3 (en)	2005-03-10	Sulfonamide substituted imidazoquinolines
EP1961752A3 (de)	2008-11-19	Piperidinverbindungen
JP2007510401A5 (de)	2007-08-09
WO2004022060A3 (en)	2004-07-08	(1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
CA2166800A1 (en)	1995-02-23	4-substituted piperidine derivatives useful as neurokinin antagonists
ATE546450T1 (de)	2012-03-15	Microkristall of (e)-8-(3,4-dimethoxystyryl)-1,3- diethyl-7-methyl-3,7-dihydro-1h-purine-2,6-dion
DK1401837T3 (da)	2005-11-07	Purinderivater som A2B-adenosinreceptorantagonister
ATE472548T1 (de)	2010-07-15	Substituierte hexahydro-pyrazino(1,2-a)pyrimidin- 4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU2003226373A1 (en)	2003-10-27	5-alkyl-7-alkylcarbonate-isoflavone ester as isoflavone prodrug
USD492325S1 (en)	2004-06-29	Pump for circulating coolant in electronic devices
USD511092S1 (en)	2005-11-01	Box blank
WO2000059449A3 (en)	2001-01-04	Purine derivatives having phosphodiesterase iv inhibition activity
AU2002258426A1 (en)	2002-09-19	Triptolide prodrugs having high aqueous solubility
PL373624A1 (en)	2005-09-05	4-[7-halo-2-quino (xa-) linyloxy]phenoxy-propionic acid derivatives as antineoplastic agents